PMD 3112
Latest Information Update: 27 Dec 2007
At a glance
- Originator Tularik
- Class
- Mechanism of Action Sodium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 12 Jul 2001 Preclinical development for Thrombosis in USA (Unknown route)
- 20 Jul 2000 Protherics has licensed PMD 3112 to Eli Lilly and Company in the USA
- 14 Mar 2000 New profile